Clinical Advances in Prostate Cancer From ESMO 2021 Clinical Advances in Prostate Cancer From ESMO 2021

Prof Johann de Bono discusses prostate cancer data from ESMO 2021, including abiraterone plus prednisolone in nonmetastatic disease, two key trials in the metastatic setting, and 177Lu-PSMA-617.Medscape
Source: Medscape Today Headlines - Category: Consumer Health News Tags: None ReCAP Source Type: news

Related Links:

In conclusion, compounds5a and6e are novel GRPR antagonists with potent anticancer activity.
Source: Medicinal Chemistry Research - Category: Chemistry Source Type: research
Condition:   Neoadjuvant Therapy \High Risk Prostate Cancer Interventions:   Other: placebo;   Drug: Proxalutamide Sponsor:   Hongqian Guo Recruiting
Source: - Category: Research Source Type: clinical trials
For prostate cancer, use of elective pelvic lymph node radiotherapy (PNRT) is controversial, and investigators have been aiming to find a role for the treatment for over 50 years. The fundamental premise for recommending PNRT is that a subset of patients with radiographic node negative disease will harbor pathologically node positive disease, and PNRT would translate into improved oncologic outcomes with minimal additional toxicity.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Source Type: research
Am J Epidemiol. 2021 Oct 13:kwab250. doi: 10.1093/aje/kwab250. Online ahead of print.ABSTRACTGrowth rate is regulated by hormonal pathways that might affect early cancer development. We explored the association between rate of growth in height from age 8 to 13 (childhood) years and from age 13 to height at study entry (adolescence), and risk of breast and prostate cancer. Participants were 2,037 Icelanders born 1915 - 1935, who took part in the Reykjavik Study established 1967. Height measures were obtained from school records and at study entry. We used multivariable Cox regression models to calculate hazard ratios with 9...
Source: Am J Epidemiol - Category: Epidemiology Authors: Source Type: research
Conclusion: [18F]-labeled tracers have high diagnostic efficacy for lymph node/bone metastasis and biochemical recurrence in advanced PCa.Urol Int
Source: Urologia Internationalis - Category: Urology & Nephrology Source Type: research
Source: World Journal of Urology - Category: Urology & Nephrology Source Type: research
Prostate Cancer and Prostatic Diseases, Published online: 13 October 2021; doi:10.1038/s41391-021-00460-yCharacterization of a castrate-resistant prostate cancer xenograft derived from a patient of West African ancestry
Source: Prostate Cancer and Prostatic Diseases - Category: Urology & Nephrology Authors: Source Type: research
AbstractIntroductionProstate-specific membrane antigen (PSMA)-based radioligand therapy (RLT) showed in a multicentre WARMTH (World Association of Radiopharmaceutical and Molecular Therapy) study that the presence of bone metastases is a negative prognosticator for the survival. The current multicentre retrospective analysis aims to evaluate the response rate to RLT, the overall survival (OS) of patients and the safety of the treatment according to the extent of bone involvement.MethodsThe study included patients with progressive metastatic castration-resistant prostate cancer (mCRPC), who underwent RLT with [177Lu]Lu-PSMA...
Source: European Journal of Nuclear Medicine and Molecular Imaging - Category: Nuclear Medicine Source Type: research
A 73-year-old man with history of grade group 1/Gleason 3 + 3 = 6 prostate adenocarcinoma status post prostatectomy had subsequent biochemical recurrence with serum prostate-specific antigen level of 2.4 ng/mL. He underwent an 18F-fluciclovine PET/CT scan that demonstrated a left prostate bed recurrence and an incidental 18F-fluciclovine–avid smooth-edged solitary lung nodule with internal fat attenuation. Such uptake of 18F-fluciclovine in a lung hamartoma could be mistaken for prostate cancer metastasis. Given the increasing use of advanced imaging for prostate cancer, there is need for the imaging specialist to kn...
Source: Clinical Nuclear Medicine - Category: Nuclear Medicine Tags: Interesting Images Source Type: research
A 51-year-old man with high-grade ductal variant of prostate cancer with normal prostate-specific antigen (PSA) levels underwent radical prostatectomy. Follow-up 18F–prostate-specific membrane antigen-targeted ligand 1007 (PSMA-1007) PET/CT revealed enlarged PSMA-expressing left common iliac node. Patient was placed on androgen deprivation therapy and was lost to follow-up. Repeat 18F-PSMA PET/CT scan after 16 months showed disease progression. PSA levels were still within normal limits. This case highlights the utility of 18F-PSMA PET/CT for staging and follow-up of patients with this rare ductal variant prostate ca...
Source: Clinical Nuclear Medicine - Category: Nuclear Medicine Tags: Interesting Images Source Type: research
More News: Cancer | Cancer & Oncology | Health | Prednisolone | Prostate Cancer